Collegium Pharmaceutical/$COLL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Ticker

$COLL
Sector
Primary listing

Employees

357

COLL Metrics

BasicAdvanced
$1.2B
35.22
$1.06
0.68
-

What the Analysts think about COLL

Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.

Bulls say / Bears say

Collegium reported record Q2 2025 net revenue of $188.0 million, up 29% year-over-year, driven by strong commercial execution across Jornay PM for ADHD as well as its pain medications (Collegium Press Release).
Management increased full-year 2025 guidance to $745–760 million in revenue and $440–455 million in adjusted EBITDA, showing confidence in sustained growth and strategic execution (Collegium Press Release).
The company generated $72.4 million in cash from operations and ended Q2 2025 with $222.2 million in cash, cash equivalents, and marketable securities. It also authorized a $150 million share repurchase program, demonstrating robust cash flow and a focus on shareholder returns (Collegium Press Release).
GAAP operating expenses soared 69% from last year to $73.3 million, while non-GAAP operating expenses climbed 104% to $61.9 million in Q2 2025, squeezing profitability (Collegium Press Release).
GAAP net income for Q2 2025 declined to $12.0 million from $19.6 million a year ago, with diluted EPS dropping to $0.34 from $0.52, signaling weaker earnings despite strong revenue growth (Collegium Press Release).
FDA approval of Vertex’s non-opioid painkiller Journavx increases competition for Collegium’s pain portfolio, and could erode market share for its opioid-based products over time (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

COLL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COLL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COLL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs